[Comparative study of molecular response of first-line and second-line nilotinib in patients with chronic-phase chronic myelogenous leukemia].
作者信息
Xu H, Wang P, Ma R J, Guo J M, Lei P C, Zang Y Z, Wang T B, Liu Z W, Yang J, Zhang Y, Zhu Z M
机构信息
Jinzhou Medical University, Jinzhou 121001, China; Hematology of Department, Henan Province People's Hospital, Zhengzhou 450003, China.
Hematology of Department, Xinyang Central Hospital, Xinyang 464000, China.
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2019 Jun 14;40(6):522-525. doi: 10.3760/cma.j.issn.0253-2727.2019.06.014.
Abstract
摘要
相似文献
1
[Comparative study of molecular response of first-line and second-line nilotinib in patients with chronic-phase chronic myelogenous leukemia].[一线和二线尼罗替尼治疗慢性期慢性髓性白血病患者分子反应的比较研究]
Zhonghua Xue Ye Xue Za Zhi. 2019 Jun 14;40(6):522-525. doi: 10.3760/cma.j.issn.0253-2727.2019.06.014.
2
Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients.尼洛替尼与达沙替尼二线治疗慢性期慢性髓性白血病患者的真实世界比较。
Ann Hematol. 2021 May;100(5):1213-1219. doi: 10.1007/s00277-021-04477-0. Epub 2021 Mar 7.
3
Cost-utility analysis of dasatinib and nilotinib in patients with chronic myeloid leukemia refractory to first-line treatment with imatinib in Thailand.达沙替尼和尼罗替尼用于泰国对伊马替尼一线治疗耐药的慢性髓性白血病患者的成本-效用分析
Clin Ther. 2014 Apr 1;36(4):534-43. doi: 10.1016/j.clinthera.2014.02.008. Epub 2014 Mar 11.
4
A critical review of trials of first-line BCR-ABL inhibitor treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase.新诊断的慢性髓性白血病慢性期患者一线 BCR-ABL 抑制剂治疗临床试验的批判性评价。
Clin Lymphoma Myeloma Leuk. 2013 Dec;13(6):646-56. doi: 10.1016/j.clml.2013.05.012. Epub 2013 Oct 1.
5
Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.达沙替尼：从治疗对伊马替尼耐药或不耐受的慢性髓性白血病患者到治疗新诊断的慢性期慢性髓性白血病患者。
Clin Ther. 2012 Feb;34(2):272-81. doi: 10.1016/j.clinthera.2012.01.009. Epub 2012 Jan 27.
6
Which tyrosine-kinase inhibitor to use first in chronic phase chronic myelogenous leukemia?在慢性期慢性粒细胞白血病中首先应使用哪种酪氨酸激酶抑制剂？
Expert Opin Pharmacother. 2015 May;16(7):999-1007. doi: 10.1517/14656566.2015.1031107. Epub 2015 Apr 3.
7
Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase.优化慢性期慢性髓性白血病患者的治疗。
Cancer. 2010 Mar 15;116(6):1419-30. doi: 10.1002/cncr.24928.
8
Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation.达沙替尼和尼洛替尼治疗伊马替尼耐药或不耐受的慢性髓性白血病：系统评价和经济评估。
Health Technol Assess. 2012;16(22):1-410. doi: 10.3310/hta16220.
9
Cost-effectiveness of dasatinib and nilotinib for imatinib-resistant or -intolerant chronic phase chronic myeloid leukemia.达沙替尼和尼洛替尼治疗伊马替尼耐药或不耐受的慢性期慢性髓性白血病的成本效益分析。
Value Health. 2011 Dec;14(8):1057-67. doi: 10.1016/j.jval.2011.07.006. Epub 2011 Oct 12.
10
Major molecular response during the first year of dasatinib, imatinib or nilotinib treatment for newly diagnosed chronic myeloid leukemia: a network meta-analysis.初诊慢性髓性白血病患者接受达沙替尼、伊马替尼或尼洛替尼治疗第一年的主要分子缓解：一项网络荟萃分析。
Cancer Treat Rev. 2014 Mar;40(2):285-92. doi: 10.1016/j.ctrv.2013.09.004. Epub 2013 Sep 17.
本文引用的文献
1
Achieving optimal response at 12 months is associated with a better health-related quality of life in patients with chronic myeloid leukemia: a prospective, longitudinal, single center study.在 12 个月时达到最佳反应与慢性髓性白血病患者更好的健康相关生活质量相关：一项前瞻性、纵向、单中心研究。
BMC Cancer. 2018 Aug 3;18(1):782. doi: 10.1186/s12885-018-4699-5.
2
Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: long-term follow-up of the Japanese subgroup of the randomized ENESTnd trial.尼洛替尼与伊马替尼治疗日本新诊断慢性期慢性髓性白血病患者的疗效比较：随机ENESTnd试验日本亚组的长期随访
Int J Hematol. 2018 Mar;107(3):327-336. doi: 10.1007/s12185-017-2353-7. Epub 2017 Oct 26.
3
Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis.尼罗替尼用于费城染色体阴性/BCR-ABL阳性慢性期慢性髓性白血病患者的一线治疗：ENEST1st亚组分析
J Cancer Res Clin Oncol. 2017 Jul;143(7):1225-1233. doi: 10.1007/s00432-017-2359-9. Epub 2017 Feb 21.
4
Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study.慢性期慢性髓性白血病患者一线使用尼洛替尼后无治疗缓解：ENESTfreedom研究结果
Leukemia. 2017 Jul;31(7):1525-1531. doi: 10.1038/leu.2017.63. Epub 2017 Feb 20.
5
The concept of treatment-free remission in chronic myeloid leukemia.慢性髓性白血病中无治疗缓解的概念。
Leukemia. 2016 Aug;30(8):1638-47. doi: 10.1038/leu.2016.115. Epub 2016 May 2.
6
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial.一线尼罗替尼与伊马替尼治疗慢性期慢性髓性白血病的长期获益与风险：随机ENESTnd试验的5年更新
Leukemia. 2016 May;30(5):1044-54. doi: 10.1038/leu.2016.5. Epub 2016 Feb 3.
7
Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study.一线尼洛替尼治疗慢性期慢性髓性白血病患者：欧洲ENEST1st研究结果
Leukemia. 2016 Jan;30(1):57-64. doi: 10.1038/leu.2015.270. Epub 2015 Oct 6.
8
Discontinuation of tyrosine kinase therapy in CML.慢性粒细胞白血病中酪氨酸激酶治疗的中断
Ann Hematol. 2015 Apr;94 Suppl 2:S187-93. doi: 10.1007/s00277-015-2320-4. Epub 2015 Mar 27.
9
Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina.尼洛替尼对比伊马替尼治疗中国新诊断慢性期慢性髓性白血病患者的3期研究：ENESTchina研究
Blood. 2015 Apr 30;125(18):2771-8. doi: 10.1182/blood-2014-09-601674. Epub 2015 Mar 12.
10
Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib.一线尼洛替尼或伊马替尼治疗的慢性期慢性髓性白血病患者的早期分子反应可预测其结局。
Blood. 2014 Feb 27;123(9):1353-60. doi: 10.1182/blood-2013-06-510396. Epub 2013 Dec 11.
Zotero 插件